An efficient supply of both health and investment in R&D -two international public goods- can only be achieved through interstate cooperation. It is a global responsibility to find a balance between the protection of property rights (ie, pharmaceutical patents) and the access to drugs at affordable prices by citizens suffering from infectious diseases in developing countries
